Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal

The FDA granted accelerated approval to neladalkib, sold as Nelkarmi, for ALK-positive non-small cell lung cancer

GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal

We haven't written up this one. Quartz has the full story — the link below goes straight to it.

Also reported by 2 other outlets

Every outlet that reported this, and when →

Read the original at qz.com →

More in Health & Medicine

More from Tuesday 17 November →